← Back to Clinical Trials
Recruiting NCT05813730

NCT05813730 Urinary Creatinine Excretion Time in the Neonatal Period

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05813730
Status Recruiting
Phase
Sponsor Central Hospital, Nancy, France
Condition Renal Function
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-10-30
Primary Completion 2025-11

Trial Parameters

Condition Renal Function
Sponsor Central Hospital, Nancy, France
Study Type INTERVENTIONAL
Phase N/A
Enrollment 40
Sex ALL
Min Age N/A
Max Age 3 Days
Start Date 2024-10-30
Completion 2025-11
Interventions
urinary creatinine excretion measurement

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Newborn's renal function is difficult to assess and its physiology during the first days of life is still incompletely known. Studies suggest that the newborn almost completely reabsorbs creatinine during the first 48 to 72 hours of life, while at the same time it continues to produce its own creatinine. Therefore, the initial stock of creatinine at birth still increases through this production and the non or weak clearance. A better knowledge of renal physiopathology in newborns would allow to improve the therapeutic management of the infants, particularly in case of potential nephrotoxicity. No study has attempted to assess the increase in urinary creatinine excretion in neonates from a given time. Objectives: To show when urinary creatinine excretion in newborns is efficient. Results: this study mightr show an inflection point in urinary creatinine excretion illustrating the postnatal age when renal function becomes efficient.

Eligibility Criteria

Inclusion Criteria: * All full-term newborns (37WA or more) * From a physiological and spontaneous pregnancy * Good neonatal adaptation (Apgar 7 at 5 minutes of life) * Eutrophic (weight \> 10th percentile and \< 90th percentile) Exclusion Criteria: * Newborns for whom no urine sample is interpretable * Those with a significant clinical-biological anomaly * Neonates with hemodynamic disorders such as low blood pressure (median \< gestational age) or hypovolemia (shock, signs of dehydration, need for volume expansion) during the first 3 days of life

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology